機能性ディスペプシア治療薬の世界市場レポート 2025年

機能性ディスペプシア治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.6％で、118億米ドルに成長すると予想されます。予測期間中の成長は、包括的でライフスタイルに基づいたアプローチに対する消費者の嗜好の高まり、併用療法に対する嗜好の高まり、ライフスタイル修正の採用の増加、腸脳軸に関する研究の拡大、非薬理学的介入の使用の増加に起因すると考えられます。この期間に予想される主な動向としては、薬剤製剤の進歩、ヘルスケアプロバイダーと製薬企業の連携、精密医療アプローチへのシフト、遠隔医療とデジタルヘルス技術の統合、個別化医療戦略などが挙げられます。

アルコール消費量の増加が機能性ディスペプシア治療薬市場の成長を押し上げると予想されます。ビール、ワイン、蒸留酒などの飲料に含まれるアルコールはエタノールで構成されており、摂取すると中枢神経系に影響を与え、中毒症状を引き起こす可能性があります。アルコール消費の増加は、社会的・文化的受容、ストレス解消、入手のしやすさ、アルコール飲料会社による積極的なマーケティングなどの要因によってもたらされています。機能性ディスペプシア治療薬は、アルコールによる胃の不快感を和らげるため、胃酸の分泌を抑え、消化機能を改善する目的で使用されます。例えば、英国の政府機関であるOHID（Office for Health Improvement &Disparities）が2023年3月に発表した報告書によると、2021～2022年にかけて、アルコールだけに関連した入院患者数は34万2,795人で、人口10万人当たりの入院患者数は626人に上ることが明らかになりました。このように、アルコール消費量の増加が機能性ディスペプシア治療薬市場の成長に寄与しています。

代謝性疾患の有病率の上昇は、機能性ディスペプシア治療薬市場の拡大を促進すると予想されます。代謝障害は、体内の正常な代謝プロセスが乱れ、栄養素やエネルギー、老廃物の処理に不均衡が生じることで発生します。食生活の乱れ、座りがちなライフスタイル、遺伝的素因、肥満率の上昇などの要因が、これらの疾患の有病率の上昇に寄与しています。機能性ディスペプシア治療薬は、代謝障害を持つ人の胃腸症状を管理し、消化機能を改善するために使用されます。例えば、世界保健機関（WHO）が2024年11月に発表した報告書によると、2022年には18歳以上の成人の14％が糖尿病と診断されました。したがって、代謝性疾患の有病率の上昇が機能性ディスペプシア治療薬市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の機能性ディスペプシア治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の機能性ディスペプシア治療薬市場：成長率分析
• 世界の機能性ディスペプシア治療薬市場の実績：規模と成長、2019～2024年
• 世界の機能性ディスペプシア治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の機能性ディスペプシア治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の機能性ディスペプシア治療薬市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• プロトンポンプ阻害剤
• H-2受容体拮抗薬
• 制酸剤
• 抗生物質
• プロキネティクス
• 抗うつ薬
• 世界の機能性ディスペプシア治療薬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 機能性ディスペプシア
• 器質性ディスペプシア
• 世界の機能性ディスペプシア治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 小売薬局
• 病院薬局
• オンライン薬局
• 世界の機能性ディスペプシア治療薬市場：プロトンポンプ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オメプラゾール
• エソメプラゾール
• ランソプラゾール
• パントプラゾール
• ラベプラゾール
• 世界の機能性ディスペプシア治療薬市場：H2受容体拮抗薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ラニチジン
• ファモチジン
• シメチジン
• ニザチジン
• 世界の機能性ディスペプシア治療薬市場：制酸剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 水酸化アルミニウム
• 水酸化マグネシウム
• 炭酸カルシウム
• 重炭酸ナトリウム
• 世界の機能性ディスペプシア治療薬市場：抗生物質のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• クラリスロマイシン
• アモキシシリン
• メトロニダゾール
• テトラサイクリン
• 世界の機能性ディスペプシア治療薬市場：プロキネティクスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ドンペリドン
• メトクロプラミド
• イトプリド
• モサプリド
• 世界の機能性ディスペプシア治療薬市場：抗うつ薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 三環系抗うつ薬
• 選択的セロトニン再取り込み阻害薬
• セロトニン・ノルエピネフリン再取り込み阻害剤

第7章 地域別・国別分析

• 世界の機能性ディスペプシア治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の機能性ディスペプシア治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 機能性ディスペプシア治療薬市場：競合情勢
• 機能性ディスペプシア治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eisai Co. Ltd.
• Menarini Group
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Daewoong Pharmaceutical Co. Ltd.
• Phathom Pharmaceuticals
• Zeria Pharmaceutical Co. Ltd.
• Ironwood Pharmaceuticals Inc.
• Salix Pharmaceuticals Inc.
• RedHill Biopharma
• RaQualia Pharma Inc.
• MetaMe Health
• Renexxion LLC
• Processa Pharmaceuticals
• Evoke Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 機能性ディスペプシア治療薬市場2029：新たな機会を提供する国
• 機能性ディスペプシア治療薬市場2029：新たな機会を提供するセグメント
• 機能性ディスペプシア治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Functional dyspepsia drugs are a category of medications used to manage and relieve symptoms related to functional dyspepsia (FD), a gastrointestinal disorder marked by persistent or recurring upper abdominal discomfort without a clear structural or biochemical cause. These medications are designed to alleviate symptoms such as bloating, early satiety, nausea, and epigastric pain.

The primary types of drugs used to treat functional dyspepsia include proton pump inhibitors, H-2 receptor antagonists, antacids, antibiotics, prokinetics, and antidepressants. Proton pump inhibitors (PPIs) are a specific type of medication that reduce stomach acid production by inhibiting the action of the gastric proton pump (H+/K+-ATPase) in the stomach lining. These treatments are commonly used for functional dyspepsia as well as organic dyspepsia and are available through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The functional dyspepsia drug market research report is one of a series of new reports from The Business Research Company that provides functional dyspepsia drug market statistics, including the functional dyspepsia drug industry's global market size, regional shares, competitors with a functional dyspepsia drug market share, detailed functional dyspepsia drug market segments, market trends and opportunities, and any further data you may need to thrive in the functional dyspepsia drug industry. This functional dyspepsia drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The functional dyspepsia drug market size has grown strongly in recent years. It will grow from $8.56 billion in 2024 to $9.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increasing prevalence of various associated risk factors, higher healthcare expenditure, a rise in dyspeptic cases, a growing number of gastrointestinal disorders, and an expanding aging population.

The functional dyspepsia drug market size is expected to see strong growth in the next few years. It will grow to $11.80 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to the rising consumer preference for holistic and lifestyle-based approaches, a growing preference for combination therapies, increased adoption of lifestyle modifications, expanding research on the gut-brain axis, and a higher use of non-pharmacological interventions. Key trends expected in this period include advancements in drug formulation, collaborations between healthcare providers and pharmaceutical companies, a shift toward precision medicine approaches, the integration of telemedicine and digital health technologies, and personalized medicine strategies.

The increase in alcohol consumption is expected to boost the growth of the functional dyspepsia drug market. Alcohol, found in beverages such as beer, wine, and spirits, is composed of ethanol, which affects the central nervous system and can cause intoxication when consumed. The rising consumption of alcohol is driven by factors such as social and cultural acceptance, stress relief, easy availability, and aggressive marketing by alcoholic beverage companies. Functional dyspepsia drugs are used to alleviate alcohol-induced gastric discomfort by reducing acid production and improving digestive function. For example, a report published by the Office for Health Improvement & Disparities (OHID) in March 2023, a UK-based government agency, revealed that between 2021 and 2022, there were 342,795 hospital admissions related solely to alcohol, leading to a rate of 626 admissions per 100,000 people. Thus, the increase in alcohol consumption is contributing to the growth of the functional dyspepsia drug market.

The rise in the prevalence of metabolic disorders is expected to drive the expansion of the functional dyspepsia drug market. A metabolic disorder occurs when the body's normal metabolic processes are disrupted, leading to an imbalance in the processing of nutrients, energy, or waste. Factors such as poor diet, sedentary lifestyles, genetic predispositions, and rising obesity rates contribute to the growing prevalence of these disorders. Functional dyspepsia drugs are used to manage gastrointestinal symptoms and improve digestive function in individuals with metabolic disorders. For instance, a report published by the World Health Organization (WHO) in November 2024 stated that 14% of adults aged 18 and older were diagnosed with diabetes in 2022. Therefore, the rising prevalence of metabolic disorders is driving the growth of the functional dyspepsia drug market.

Leading companies in the functional dyspepsia drug market are focusing on clinical trials to develop innovative therapies that address the underlying causes of the condition, improve treatment effectiveness, and meet patient needs. Clinical trials are crucial for assessing the safety, efficacy, and optimal treatment strategies for functional dyspepsia drugs. For example, in December 2022, electroCore Inc., a US-based medical technology company, announced that the United States Patent and Trademark Office (USPTO) granted two patents for its innovative non-invasive vagus nerve stimulation (nVNS) technology. The first patent, U.S. Patent No. 11,511,109, covered a method for treating gastrointestinal disorders, including functional dyspepsia, using vagus nerve stimulation. The second patent, U.S. Patent No. 11,511,110, involved a system for delivering non-invasive electrical stimulation to the vagus nerve. These patents reinforced electroCore's position in advancing non-invasive neuromodulation therapies.

Major players in the functional dyspepsia drug market are Pfizer Inc., Abbvie Inc., Bayer AG, AstraZeneca plc, Astellas Pharma Inc., Eisai Co. Ltd., Menarini Group, Dr. Reddy's Laboratories Ltd., Lupin Limited, Daewoong Pharmaceutical Co. Ltd., Phathom Pharmaceuticals, Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Salix Pharmaceuticals Inc., RedHill Biopharma, RaQualia Pharma Inc., MetaMe Health, Renexxion LLC, Processa Pharmaceuticals, and Evoke Pharma Inc.

North America was the largest region in the functional dyspepsia drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in functional dyspepsia drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the functional dyspepsia drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The functional dyspepsia drug market consists of sales of mucosal protectants, neuromodulators, serotonin modulators, and herbal drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Functional Dyspepsia Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on functional dyspepsia drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for functional dyspepsia drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The functional dyspepsia drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Proton Pump Inhibitors; H-2-Receptor Antagonists; Antacids; Antibiotics; Prokinetics; Antidepressants
• 2) By Indication: Functional Dyspepsia; Organic Dyspepsia
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
• 2) By H-2-Receptor Antagonists: Ranitidine; Famotidine; Cimetidine; Nizatidine
• 3) By Antacids: Aluminum Hydroxide; Magnesium Hydroxide; Calcium Carbonate; Sodium Bicarbonate
• 4) By Antibiotics: Clarithromycin; Amoxicillin; Metronidazole; Tetracycline
• 5) By Prokinetics: Domperidone; Metoclopramide; Itopride; Mosapride
• 6) By Antidepressants: Tricyclic Antidepressants; Selective Serotonin Reuptake Inhibitors; Serotonin-Norepinephrine Reuptake Inhibitors
• Companies Mentioned: Pfizer Inc.; Abbvie Inc.; Bayer AG; AstraZeneca plc; Astellas Pharma Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Functional Dyspepsia Drug Market Characteristics

3. Functional Dyspepsia Drug Market Trends And Strategies

4. Functional Dyspepsia Drug Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Functional Dyspepsia Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Functional Dyspepsia Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Functional Dyspepsia Drug Market Growth Rate Analysis
• 5.4. Global Functional Dyspepsia Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Functional Dyspepsia Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Functional Dyspepsia Drug Total Addressable Market (TAM)

6. Functional Dyspepsia Drug Market Segmentation

• 6.1. Global Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors
• H-2-Receptor Antagonists
• Antacids
• Antibiotics
• Prokinetics
• Antidepressants
• 6.2. Global Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Functional Dyspepsia
• Organic Dyspepsia
• 6.3. Global Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.4. Global Functional Dyspepsia Drug Market, Sub-Segmentation Of Proton Pump Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Esomeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• 6.5. Global Functional Dyspepsia Drug Market, Sub-Segmentation Of H-2-Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranitidine
• Famotidine
• Cimetidine
• Nizatidine
• 6.6. Global Functional Dyspepsia Drug Market, Sub-Segmentation Of Antacids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aluminum Hydroxide
• Magnesium Hydroxide
• Calcium Carbonate
• Sodium Bicarbonate
• 6.7. Global Functional Dyspepsia Drug Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clarithromycin
• Amoxicillin
• Metronidazole
• Tetracycline
• 6.8. Global Functional Dyspepsia Drug Market, Sub-Segmentation Of Prokinetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Domperidone
• Metoclopramide
• Itopride
• Mosapride
• 6.9. Global Functional Dyspepsia Drug Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tricyclic Antidepressants
• Selective Serotonin Reuptake Inhibitors
• Serotonin-Norepinephrine Reuptake Inhibitors

7. Functional Dyspepsia Drug Market Regional And Country Analysis

• 7.1. Global Functional Dyspepsia Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Functional Dyspepsia Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Functional Dyspepsia Drug Market

• 8.1. Asia-Pacific Functional Dyspepsia Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Functional Dyspepsia Drug Market

• 9.1. China Functional Dyspepsia Drug Market Overview
• 9.2. China Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Functional Dyspepsia Drug Market

• 10.1. India Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Functional Dyspepsia Drug Market

• 11.1. Japan Functional Dyspepsia Drug Market Overview
• 11.2. Japan Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Functional Dyspepsia Drug Market

• 12.1. Australia Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Functional Dyspepsia Drug Market

• 13.1. Indonesia Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Functional Dyspepsia Drug Market

• 14.1. South Korea Functional Dyspepsia Drug Market Overview
• 14.2. South Korea Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Functional Dyspepsia Drug Market

• 15.1. Western Europe Functional Dyspepsia Drug Market Overview
• 15.2. Western Europe Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Functional Dyspepsia Drug Market

• 16.1. UK Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Functional Dyspepsia Drug Market

• 17.1. Germany Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Functional Dyspepsia Drug Market

• 18.1. France Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Functional Dyspepsia Drug Market

• 19.1. Italy Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Functional Dyspepsia Drug Market

• 20.1. Spain Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Functional Dyspepsia Drug Market

• 21.1. Eastern Europe Functional Dyspepsia Drug Market Overview
• 21.2. Eastern Europe Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Functional Dyspepsia Drug Market

• 22.1. Russia Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Functional Dyspepsia Drug Market

• 23.1. North America Functional Dyspepsia Drug Market Overview
• 23.2. North America Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Functional Dyspepsia Drug Market

• 24.1. USA Functional Dyspepsia Drug Market Overview
• 24.2. USA Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Functional Dyspepsia Drug Market

• 25.1. Canada Functional Dyspepsia Drug Market Overview
• 25.2. Canada Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Functional Dyspepsia Drug Market

• 26.1. South America Functional Dyspepsia Drug Market Overview
• 26.2. South America Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Functional Dyspepsia Drug Market

• 27.1. Brazil Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Functional Dyspepsia Drug Market

• 28.1. Middle East Functional Dyspepsia Drug Market Overview
• 28.2. Middle East Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Functional Dyspepsia Drug Market

• 29.1. Africa Functional Dyspepsia Drug Market Overview
• 29.2. Africa Functional Dyspepsia Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Functional Dyspepsia Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Functional Dyspepsia Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Functional Dyspepsia Drug Market Competitive Landscape And Company Profiles

• 30.1. Functional Dyspepsia Drug Market Competitive Landscape
• 30.2. Functional Dyspepsia Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Functional Dyspepsia Drug Market Other Major And Innovative Companies

• 31.1. Eisai Co. Ltd.
• 31.2. Menarini Group
• 31.3. Dr. Reddy's Laboratories Ltd.
• 31.4. Lupin Limited
• 31.5. Daewoong Pharmaceutical Co. Ltd.
• 31.6. Phathom Pharmaceuticals
• 31.7. Zeria Pharmaceutical Co. Ltd.
• 31.8. Ironwood Pharmaceuticals Inc.
• 31.9. Salix Pharmaceuticals Inc.
• 31.10. RedHill Biopharma
• 31.11. RaQualia Pharma Inc.
• 31.12. MetaMe Health
• 31.13. Renexxion LLC
• 31.14. Processa Pharmaceuticals
• 31.15. Evoke Pharma Inc.

32. Global Functional Dyspepsia Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Functional Dyspepsia Drug Market

34. Recent Developments In The Functional Dyspepsia Drug Market

35. Functional Dyspepsia Drug Market High Potential Countries, Segments and Strategies

• 35.1 Functional Dyspepsia Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Functional Dyspepsia Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Functional Dyspepsia Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer